Integrating liver endpoints in clinical trials of cardiovascular and kidney disease
The intersection of cardiovascular disease, metabolic disorders and chronic kidney disease
represents a complex clinical picture challenging healthcare systems worldwide. Metabolic …
represents a complex clinical picture challenging healthcare systems worldwide. Metabolic …
Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Hepatology AASLD Publications Hepatology Liver Transplantation Hepatology
Communications Clinical Liver Disease Log in or Register Subscribe to journalSubscribe Get …
Communications Clinical Liver Disease Log in or Register Subscribe to journalSubscribe Get …
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
AJ Sanyal, SS Shankar, KP Yates, J Bolognese… - Nature medicine, 2023 - nature.com
There are no approved diagnostic biomarkers for at-risk non-alcoholic steatohepatitis
(NASH), defined by the presence of NASH, high histological activity and fibrosis stage≥ 2 …
(NASH), defined by the presence of NASH, high histological activity and fibrosis stage≥ 2 …
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
European Association for the Study of the Liver (EASL)… - Obesity Facts, 2024 - karger.com
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …
[HTML][HTML] Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual …
Background Histologically assessed liver fibrosis stage has prognostic significance in
patients with non-alcoholic fatty liver disease (NAFLD) and is accepted as a surrogate …
patients with non-alcoholic fatty liver disease (NAFLD) and is accepted as a surrogate …
A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis
The current diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD)
and its severe form, metabolic dysfunction-associated steatohepatitis (MASH), is suboptimal …
and its severe form, metabolic dysfunction-associated steatohepatitis (MASH), is suboptimal …
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis
SA Harrison, V Ratziu, QM Anstee… - Alimentary …, 2024 - Wiley Online Library
Background Non‐alcoholic steatohepatitis (NASH) is a progressive form of non‐alcoholic
fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and …
fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and …
Precision medicine in fatty liver disease/non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, and is
related to fatal and non-fatal liver, metabolic, and cardiovascular complications. Its non …
related to fatal and non-fatal liver, metabolic, and cardiovascular complications. Its non …
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
The rising prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD)
poses a significant global health challenge, affecting over 30% of adults worldwide. MASLD …
poses a significant global health challenge, affecting over 30% of adults worldwide. MASLD …